Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease

Documenti analoghi

• Long‐Term Treatment With Subcutaneous Treprostinil in Patients With Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension in the Multimodal Therapy Era (Data From CTREPH Study Open Label Extension)
  di: Pavel Jansa, et al.
  Pubblicazione: (2025)
• Inhaled Treprostinil in PH‐ILD: Interpreting Claims‐Based Reductions in Hospitalizations
  di: Teja Narra
  Pubblicazione: (2026)
• Real‐World Comparison of Patients With PH‐ILD Initiating Inhaled Treprostinil Versus Patients Who Remain Untreated
  di: Steven J. Cassady, et al.
  Pubblicazione: (2025)
• Early Experience of Treprostinil Dry‐Powdered Inhaler in Patients With Pulmonary Hypertension Related to Fibrosing Interstitial Lung Disease at a Tertiary Referral Center
  di: Jordin L. Rice, et al.
  Pubblicazione: (2026)
• Recognition, diagnosis, and operability assessment of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross‐sectional scientific survey (CLARITY)
  di: Grzegorz Kopeć, et al.
  Pubblicazione: (2024)